[news] azithromycin for Puli pharmaceutical injection is on the market in the Netherlands! The first one in China to pass the consistency evaluation, what is the market situation?

On October 31, Hainan Puli Pharmaceutical Co., Ltd (hereinafter referred to as "Puli pharmaceutical") announced that it had recently received the marketing license of azithromycin 500mg for injection issued by the Dutch drug evaluation committee, and the indications were community acquired pneumonia and pelvic inflammatory diseases caused by sensitive pathogens Azithromycin is the second generation of macrolide antibiotics It was first discovered by Pliva in 1980 and patented in 1981 In 1986, Pliva transferred its sales rights in Western Europe and the United States to Pfizer, and its products were sold in central and Eastern Europe in 1988 In 1997, Pfizer was approved to be listed in the United States by azithromax for injection, and in 2007, it was approved to be listed in China by import yuanyan (trade name: xishumei) Azithromycin for injection has been widely sold in the world Puli pharmaceutical's Azithromycin for injection has opened another foreign market, which is gratifying According to Puli pharmaceutical's announcement, in addition to the Dutch market, Puli pharmaceutical's product received the formal approval of the US Food and Drug Administration on October 9, 2018; it obtained the marketing license issued by the Austrian drug administration in October 2018; in addition, Puli pharmaceutical has also opened a market in the EU, Australia, Canada, etc The market has submitted an application for listing So apart from opening up foreign markets, what are the market opportunities at home? Domestic marketing situation: Puli pharmaceutical was approved in August 2017, and passed the consistency evaluation of quality and efficacy of chemical generic drugs in May 2018 According to the domestic drug database of pharmaceutical intelligence, at present, there are 64 enterprises holding approval documents of azithromycin for injection in China, involving 5 specifications, and all of them are listed in class B of national medical insurance According to the bid winning information query database of Yaozhi, the bid winning situation of 0.5g (500000 units) of azithromycin for injection enterprises is shown in the figure below Pfizer won the bid in 30 regions with the highest price, with an average price of 103.39 yuan In China, Henan Furen huaiqingtang, Hunan Kelun, Shandong Luoxin, Chenxin pharmaceutical, Sinopharm group and Zhejiang Asia Pacific pharmaceutical won more bids According to the overall bid winning situation of a specification, we can see that the market of the drug has been greatly saturated at present Puli pharmaceutical has opened up the foreign market, which is a good way to develop For the domestic market, the advantages of consistency evaluation may open a new competition pattern for it In 2007-2018, the bid winning situation of 0.5g (500000 units) * 1 azithromycin for injection and the domestic consistency evaluation situation are as follows: at present, the related drugs of azithromycin are listed in the catalogue of drugs on the market in China The domestic stone drug Ouyi's Azithromycin tablet, the azithromycin capsule of Suzhou Erye pharmaceutical and the azithromycin for injection of Puli pharmaceutical are all the first ones to enter However, at present, only four enterprises have made reference to the progress of application for conformity assessment of azithromycin for injection, and there is no other relevant information Puli pharmaceutical, as the first one to enter the catalogue of Chinese listed drugs, has great advantages Information source: Puli pharmaceutical announcement data source: Pharmaceutical intelligence data statement: This article is the integrated content of pharmaceutical intelligence network, and the copyright belongs to the original author, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact with this website message, we will delete the content in the first time!